Cancer Stem Cell Targeting via Marker-Based Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for breast, prostate, lung, colorectal, and head and neck cancers are limited by their inability to effectively target and treat cancer stem cells, leading to incomplete detection and treatment of phenotypic diversity in tumors.
Innovation Solution
Identification and isolation of cancer stem cells using specific gene expression profiles and markers such as CD44, CD166, CD59, and ALDH activity, followed by enrichment and characterization methods like flow cytometry and fluorescence-activated cell sorting, to develop targeted therapeutic strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic and therapeutic approaches are used, then treatment is provided, but cancer stem cells cannot be effectively targeted leading to incomplete detection and treatment
Solution Approach 1:
The patent segments the heterogeneous tumor cell population into distinct subpopulations based on stem cell markers (CD44, CD166, CD59, ALDH activity). This segmentation allows specific targeting of cancer stem cells that are responsible for tumor initiation, progression, and metastasis, thereby improving treatment effectiveness and detection accuracy simultaneously.
Solution Approach 2:
The patent extracts and isolates cancer stem cells from the bulk tumor population using flow cytometry and fluorescence-activated cell sorting based on their unique marker expression profiles. This extraction enables focused therapeutic intervention on the critical stem cell subpopulation, resolving the contradiction between providing general treatment and achieving precise targeting.
2Adaptability or versatility
If phenotypic diversity in tumors is addressed, then treatment completeness improves, but current tools fail to detect and treat this diversity
Solution Approach 1:
The patent applies local quality by identifying and characterizing specific phenotypic subsets within the tumor population through marker expression analysis. Different tumor cell subsets are distinguished by their unique combinations of stem cell markers (e.g., CD44+, CD166+, CD59+, ALDH+), enabling tailored therapeutic strategies for each phenotypic group while maintaining overall treatment coverage.
3Ease of manufacture
If cancer stem cells are isolated and characterized, then targeted therapy can be developed, but complex isolation and enrichment procedures are required
Solution Approach 1:
The patent establishes a universal panel of stem cell markers (CD44, CD166, CD59, ALDH) that can be used across different cancer types and patient samples. This multi-functional marker set enables consistent isolation and characterization of cancer stem cells using standardized flow cytometry and sorting procedures, simplifying the overall process while maintaining high purity and functional relevance.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.